James Mitchum
Chief Executive Officer at Regalorx
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gary B. Morsch | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | 32 years |
James Kerr | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | 32 years |
Christopher Giordano | M | 50 | 3 years | |
Kim Carroll | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | 8 years |
June Almenoff | M | 67 | 3 years | |
Declan Doogan | M | 72 | 3 years | |
M. A. Chaudry | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
Michael Davidson | M | 67 | 3 years | |
Carla Duryee | F | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
Richard J. Randolph | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
Stuart Rich | M | 74 | 3 years | |
Daniel McClain | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
Dan Neal | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | 25 years |
James Zeeb | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
Jon North | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
Wendy Blackburn | F | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
Austin Bickford | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
David Allyn | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
Larry R. Downey | M | 71 |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
Lee A. Norman | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
Susan Garrett | F | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
Maurice Lee | M | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Pierre Legault | M | 63 |
Hoechst Marion Roussel, Inc.
| 7 years |
John Kelley | M | 70 |
Hoechst Marion Roussel, Inc.
| 9 years |
John Hamill | M | 60 | 3 years | |
Ronald Blanck | M | 82 | 12 years | |
Nancy J. Hecox | F | - | 12 years | |
Anthony DiTonno | M | 75 | 10 years | |
Marco Taglietti | M | 64 | 3 years | |
Illya Keith Maher | M | 56 | 2 years | |
Steven Boyd | M | 43 | 2 years | |
Gregory Pepin | M | 41 | 12 years | |
Chris Rallis | M | 70 | 10 years | |
Rhonda L. Stanley | F | 64 | 1 years | |
Cyrille Leperlier | M | 70 |
Sanofi-Aventis Japan
| 15 years |
Timothy L. Miller | M | 67 |
Hoechst Marion Roussel, Inc.
| 18 years |
John J. Harrington | M | - |
Hoechst Marion Roussel, Inc.
| 1 years |
Charles W. Gorodetzky | M | 86 |
Hoechst Marion Roussel, Inc.
| 4 years |
Shane Schaffer | M | 49 |
Hoechst Marion Roussel, Inc.
| 2 years |
John Brandmeyer | M | - |
Enturia, Inc.
Enturia, Inc. Medical SpecialtiesHealth Technology Enturia, Inc. develops and manufactures medical devices and drugs. Its products include Swabstick 1.75mL, Sepp 0.67mL and Frepp1.5mL. The company research and develops products which cures human health diseases. Enturia was founded by Joseph A. Brandmeyer in 1985 and is headquartered in Leawood, KS. | 1 years |
Mark A. Birrell | M | 56 |
Aventis Pharma UK
| - |
Iain Robert McGill | M | 51 |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | 2 years |
Krystal Barr | F | - |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | 2 years |
Jean-Francois Leprince | M | - |
Hoechst Marion Roussel, Inc.
| 6 years |
Roland Baron | M | - |
Hoechst Marion Roussel, Inc.
| 8 years |
Adam Townsend | M | 47 |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | 1 years |
Jaikrishna Patel | M | - | 1 years | |
Andreas Busch | M | 59 |
Hoechst Marion Roussel, Inc.
| 2 years |
William A. Sumner | M | 86 |
Hoechst Marion Roussel, Inc.
| 21 years |
Timothy Corn | M | 73 |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | - |
David H. Bergstrom | M | 70 |
Hoechst Marion Roussel, Inc.
| 2 years |
Gillian C. Ivers-Read | F | 70 |
Hoechst Marion Roussel, Inc.
| 5 years |
James A. Byrnes | M | 77 |
Hoechst Marion Roussel, Inc.
| - |
Gerry Proehl | M | 65 |
Hoechst Marion Roussel, Inc.
| 2 years |
Colin Broom | M | 68 |
Hoechst Marion Roussel, Inc.
| 1 years |
Deepak Shripad Phadke | M | 73 |
Hoechst Marion Roussel, Inc.
| 12 years |
Juergen Lasowski | M | 66 |
Hoechst Marion Roussel, Inc.
| 11 years |
Frank Douglas | M | 80 |
Hoechst Marion Roussel, Inc.
| 4 years |
David John Cook | M | 57 |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | 5 years |
Norbert Riedel | M | 66 |
Hoechst Marion Roussel, Inc.
| 2 years |
Mark A. Klausner | M | 71 | - | |
Martin Zeiger | M | 87 |
Hoechst Marion Roussel, Inc.
| - |
Martin Vogelbaum | M | 60 | 1 years | |
Kevin J. Bratton | M | 75 |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | 1 years |
Dan Cabo | M | - | 7 years | |
Errol de Souza | M | 70 |
Hoechst Marion Roussel, Inc.
| 4 years |
Benjamin Warriner | M | - |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 65 | 97.01% |
United Kingdom | 1 | 1.49% |
Japan | 1 | 1.49% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Mitchum
- Personal Network